methamphetamine has been researched along with Parkinson Disease in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.14) | 18.7374 |
| 1990's | 10 (14.29) | 18.2507 |
| 2000's | 27 (38.57) | 29.6817 |
| 2010's | 23 (32.86) | 24.3611 |
| 2020's | 5 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, JH; Katila, N; Lee, S; Seo, JH; Shrestha, P; Yook, S | 1 |
| Guo, S; Hui, T | 1 |
| Jang, WJ; Jeong, CH; Lee, S; Ryu, IS; Son, T; Song, SH | 1 |
| Aoun, K; Berg, D; Double, KL; Pearson-Dennett, V; Todd, G; Yilmaz, R | 1 |
| Desai Bradaric, B; Graves, SM; Kelly, LP; Kousik, SM; Napier, TC; Persons, AL; Yamamoto, BK | 1 |
| Darke, S; Farrell, M; Lappin, JM | 1 |
| Baucum, AJ; Edler, MC; Kaur, H; Morris, CW; Salek, AB; Watkins, DS; Yamamoto, BK | 1 |
| Ceccatelli, S | 1 |
| Chen, L; Huang, E; Liu, C; Qiu, P; Wang, H | 1 |
| Ageta-Ishihara, N; Hattori, S; Kinoshita, M; Miyakawa, T; Morita, T; Takahashi, R; Takao, K; Yamakado, H | 1 |
| Jiang, W; Li, J; Wang, H; Wang, Z; Zhang, Z | 1 |
| Boileau, I; Callaghan, RC; Kish, SJ; Tong, J | 1 |
| Baldwin, HA; Harvey, BK; Koivula, PP; Necarsulmer, JC; Whitaker, KW | 1 |
| Brocker, DT; Grill, WM; Gross, RE; So, RQ; Swan, BD; Turner, DA | 1 |
| Chou, J; Ebendal, T; Harvey, BK; Hoffer, B; Wang, Y | 1 |
| Abe, H; Ebihara, K; Hashiguchi, H; Ishida, Y; Kawai, K; Magata, Y; Matsuo, H; Nishimori, T; Odagiri, K; Takeda, R; Yoshimoto, M | 1 |
| Boileau, I; Guttman, M; Houle, S; Kish, SJ; Rusjan, P; Saint-Cyr, JA; Selby, P; Tong, J; Wilkins, D; Wilson, AA | 1 |
| Aoki, Y; Endo, S; Fujino, Y; Fujita, Y; Inoue, Y; Niitsu, H; Onodera, M; Takahashi, K; Takei, M | 1 |
| Fornai, F; Paparelli, A; Pasquali, L; Ruffoli, R; Ruggieri, S; Soldani, P | 1 |
| Iida, A; Inoue, N; Kakiuchi, T; Kondo, Y; Muramatsu, S; Nakano, I; Nakayama, T; Okuno, T; Ono, F; Suzuki, Y; Takino, N; Terao, K; Tsukada, H | 1 |
| Fu, Y; Fujita, Y; Hirayama, M; Ichihara, M; Ito, M; Kajita, Y; Maesawa, S; Masuda, A; Ohno, K; Ohsawa, I; Ohta, S; Suzuki, Y | 1 |
| Bourque, M; Di Paolo, T; Dluzen, DE | 1 |
| Biagioni, F; Fornai, F; Murri, L; Paparelli, A; Pellegrini, A; Ruggieri, S | 1 |
| Bach, JH; Bing, G; Jin, CH; Jung, BD; Kim, HC; Nah, SY; Nguyen, XK; Park, SJ; Shin, EJ; Wie, MB | 1 |
| Alberto, JM; Arango-Rodriguez, ML; Ayala-Davila, J; Battaglia-Hsu, SF; Chery, C; Daval, JL; Gueant, JL; Martinez-Fong, D; Orozco-Barrios, CE; Schroeder, H | 1 |
| Baes, M; Juri, C; Rubio, FJ; Somoza, R; Wyneken, U | 1 |
| Akamine, S; Fang, X; Namba, H; Sugiyama, K; Sun, W | 1 |
| Callaghan, RC; Cunningham, JK; Kish, SJ; Sajeev, G | 1 |
| Becker, KG; Brannock, C; Cadet, JL; Chou, J; Krasnova, IN; Ladenheim, B; Lehrmann, E; McCoy, MT; Wang, Y; Wood, WH | 1 |
| McIntire, SL; Schreiber, MA | 1 |
| Elsworth, JD; Morrow, BA; Redmond, DE; Roth, RH | 1 |
| Kuehn, BM | 1 |
| Blesa, J; Jackson-Lewis, V; Przedborski, S | 1 |
| Breger, LS; Dunnett, SB; Lane, EL; Smith, GA | 1 |
| Napier, TC; Riddle, JL; Rokosik, SL | 1 |
| Lee, JS; Tavassoly, O | 1 |
| Dimpfel, W; Hoffmann, JA; Müller, T; Oehlwein, C | 1 |
| Martínez-Alonso, E; Martínez-Martínez, N; Martínez-Menárguez, JA; Rendón, WO; Tomás, M | 1 |
| Brooks, DJ; Pavese, N; Piccini, P | 1 |
| Ahlner, J; Dizdar, N; Kronstrand, R; Larson, G | 1 |
| Holden, C | 1 |
| Anderson, LI; Dluzen, DE; Gajjar, TM | 1 |
| Brooks, DJ; Gerhard, A; Pavese, N; Piccini, P; Rimoldi, O | 1 |
| Chen, GJ; Chou, J; Harvey, BK; Hoffer, BJ; Mark, A; Wang, Y | 1 |
| Brundin, P; Dringen, R; Falsig, J; Leist, M; Lotharius, J; Payne, S; van Beek, J | 1 |
| LaVoie, MJ; Ostaszewski, BL; Schlossmacher, MG; Selkoe, DJ; Weihofen, A | 1 |
| Ikeda, N; Inoue, N; Itoh, S; Kudo, K; Nishida, K | 1 |
| Dluzen, DE; Liu, B | 1 |
| Flumerfelt, BA; Hrycyshyn, AW; Rajakumar, B; Rajakumar, N | 1 |
| Hardie, RJ; Lees, AJ; Sandler, M; Stern, GM | 1 |
| Calne, DB; Chuang, LW; Eisler, T; Karoum, F; Klein, DF; Liebowitz, MR; Quitkin, FM; Wyatt, RJ | 1 |
| Elsworth, JD; Lees, AJ; Sandler, M; Stern, GM; Ward, C | 1 |
| Bosc, M; Deffond, D; Dordain, G; Dostert, P; Fiorentini, F; La Croix, R; Persiani, S; Strolin Benedetti, M; Vernay, D | 1 |
| Brannock, C; Cadet, JL | 1 |
| Adams, FS; Bell, KP; Clarkson, ED; Freed, CR; Zawada, WM | 1 |
| Green, S; Jakowec, MW; Petzinger, GM; Tolwani, RJ; Waggie, K | 1 |
| Björklund, A; Brooks, DJ; Brundin, P; Grasby, PM; Gunn, RN; Hagell, P; Lindvall, O; Piccini, P; Rehncrona, S; Rimoldi, O; Widner, H | 1 |
| Hastings, TG; LaVoie, MJ | 1 |
| Fujimoto, I; Hashimoto, M; Hida, H; Mikoshiba, K; Nagatsu, T; Nakajima, K; Nishino, H; Shimano, Y | 1 |
| Bing, G; Choi, DY; Floyd, RA; Im, DH; Jhoo, WK; Kim, HC; Shin, EJ; Suh, JH | 1 |
| Harvey, DC; Laćan, G; Melegan, WP | 1 |
| Bocsi, J; Bökönyi, G; Kéri, G; Magyar, K; Szende, B; Timár, F | 1 |
| Davidson, C; Ellinwood, EH; Gow, AJ; Lee, TH | 1 |
| Guilarte, TR | 1 |
| Brown, VM; Cherry, SR; Khan, AH; Lacan, G; Leahy, RM; Melega, WP; Ossadtchi, A; Smith, DJ; Yee, S | 1 |
| Bell, KP; Bjugstad, KB; Clarkson, ED; Freed, CR; Hutt, C; Marrack, P; Veng, LM; Zawada, WM | 1 |
| Hassler, R; Wagner, A | 1 |
| Wagner, GC; Walsh, SL | 1 |
| Close, SP; Elliott, PJ; Hayes, AG; Marriott, AS; Walsh, DM | 1 |
| Jurna, I | 1 |
12 review(s) available for methamphetamine and Parkinson Disease
| Article | Year |
|---|---|
Methamphetamine induced neurotoxic diseases, molecular mechanism, and current treatment strategies.
Topics: Amphetamine-Related Disorders; Astrocytes; Central Nervous System Stimulants; Humans; Methamphetamine; Neurotoxicity Syndromes; Parkinson Disease | 2022 |
Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications.
Topics: Central Nervous System Stimulants; Evidence-Based Medicine; Female; Forecasting; Humans; Male; Methamphetamine; Parkinson Disease; Risk Factors; Smoking | 2018 |
Mechanisms of neurotoxicity and implications for neurological disorders.
Topics: Anti-HIV Agents; Central Nervous System Stimulants; Congresses as Topic; Hazardous Substances; Humans; Manganese; Methamphetamine; Nervous System Diseases; Neurotoxicity Syndromes; Neurotoxins; Parkinson Disease; Receptors, Dopamine; Risk Factors; Trace Elements | 2013 |
Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.
Topics: Animals; Central Nervous System Stimulants; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Humans; Methamphetamine; Parkinson Disease | 2017 |
Neuroprotective actions of sex steroids in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopamine Agents; Estrogens; Humans; Methamphetamine; Mitogen-Activated Protein Kinases; Neural Pathways; Neuroprotective Agents; Parkinson Disease; Phosphatidylinositol 3-Kinases; Progesterone; Receptors, Estrogen; Sex Characteristics; Signal Transduction; Steroids | 2009 |
Behavioural sensitisation during dopamine replacement therapy in Parkinson's disease is reminiscent of the addicted brain.
Topics: Animals; Behavior, Addictive; Brain; Humans; Levodopa; Methamphetamine; Parkinson Disease | 2009 |
Animal models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Humans; Insecticides; Methamphetamine; MPTP Poisoning; Oxidopamine; Parkinson Disease | 2012 |
Free radicals and the pathobiology of brain dopamine systems.
Topics: Animals; Brain; Dopamine; Free Radicals; Humans; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Reactive Oxygen Species | 1998 |
Experimental models of Parkinson's disease: insights from many models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Humans; Methamphetamine; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Reserpine | 1999 |
Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment.
Topics: Amphetamine-Related Disorders; Animals; Apoptosis; Central Nervous System; Disease Models, Animal; Drug Administration Schedule; Humans; Methamphetamine; Necrosis; Nerve Degeneration; Neurotoxins; Parkinson Disease | 2001 |
Is methamphetamine abuse a risk factor in parkinsonism?
Topics: Amphetamine-Related Disorders; Animals; Central Nervous System Stimulants; Dopamine; Humans; Methamphetamine; Parkinson Disease | 2001 |
Locomotor activity and speed of movements in relation to monoamine-acting drugs.
Topics: Animals; Atropine; Basal Ganglia; Cats; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Harmaline; Humans; Hydroxydopamines; Methamphetamine; Motor Activity; Motor Neurons; Norepinephrine; Parkinson Disease; Rats; Reserpine; Substantia Nigra | 1975 |
3 trial(s) available for methamphetamine and Parkinson Disease
| Article | Year |
|---|---|
Quantitative analysis of desmethylselegiline, methamphetamine, and amphetamine in hair and plasma from Parkinson patients on long-term selegiline medication.
Topics: Aged; Aged, 80 and over; Amphetamine; Amphetamines; Antiparkinson Agents; Drug Administration Schedule; Female; Hair; Hair Color; Humans; Male; Melanins; Methamphetamine; Middle Aged; Parkinson Disease; Patient Compliance; Selegiline; Spectrophotometry | 2003 |
Cardiovascular effects of methamphetamine in Parkinson's disease patients.
Topics: Adrenergic Fibers; Analysis of Variance; Blood Pressure; Brain; Catecholamines; Dopamine Agents; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Injections, Intravenous; Levodopa; Male; Methamphetamine; Middle Aged; Myocardium; Parkinson Disease; Presynaptic Terminals; Psychomotor Agitation; Tomography, Emission-Computed | 2004 |
Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline.
Topics: Aged; Amphetamine; Amphetamines; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Interactions; Ergolines; Female; Humans; Male; Methamphetamine; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 1995 |
55 other study(ies) available for methamphetamine and Parkinson Disease
| Article | Year |
|---|---|
Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report.
Topics: Adult; Dopamine; Humans; Male; Methamphetamine; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease; Substance-Related Disorders | 2023 |
Transcriptional Profiling of Whisker Follicles and of the Striatum in Methamphetamine Self-Administered Rats.
Topics: Alzheimer Disease; Amphetamine-Related Disorders; Animals; Corpus Striatum; Disease Models, Animal; Gene Expression Regulation; Hair Follicle; High-Throughput Nucleotide Sequencing; Humans; Huntington Disease; Methamphetamine; Neostriatum; Parkinson Disease; Rats; Self Administration; Signal Transduction; Transcriptome; Vibrissae | 2020 |
Measurement of the adult human midbrain with transcranial ultrasound.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Female; Humans; Male; Mesencephalon; Methamphetamine; Middle Aged; Parkinson Disease; Substantia Nigra; Ultrasonography, Doppler, Transcranial; Young Adult | 2021 |
Gut and brain profiles that resemble pre-motor and early-stage Parkinson's disease in methamphetamine self-administering rats.
Topics: alpha-Synuclein; Animals; Brain; Methamphetamine; Parkinson Disease; Rats; Substantia Nigra | 2021 |
Mechanisms Regulating the Association of Protein Phosphatase 1 with Spinophilin and Neurabin.
Topics: Amphetamine-Related Disorders; Animals; Corpus Striatum; Cyclin-Dependent Kinase 5; Dopamine Agents; Methamphetamine; Mice; Mice, Knockout; Microfilament Proteins; Nerve Tissue Proteins; Parkinson Disease; Phosphorylation; Protein Phosphatase 1; Rats; Rotarod Performance Test | 2018 |
RNA interference targeting α-synuclein attenuates methamphetamine-induced neurotoxicity in SH-SY5Y cells.
Topics: alpha-Synuclein; Blotting, Western; Cell Line, Tumor; Cell Survival; Central Nervous System Stimulants; Enzyme-Linked Immunosorbent Assay; Gene Knockdown Techniques; Humans; Methamphetamine; Neurons; Parkinson Disease; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA Interference; Transfection | 2013 |
Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson's disease, causes behavioral alterations but not neurodegeneration in mice.
Topics: alpha-Synuclein; Animals; Behavior, Animal; Circadian Rhythm; Dopamine; Dopamine Plasma Membrane Transport Proteins; Exploratory Behavior; Humans; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neostriatum; Nerve Degeneration; Parkinson Disease; Peptides; Protein Structure, Quaternary; Rats; Septins; Solubility; Substrate Specificity; Tyrosine 3-Monooxygenase; Ubiquitin-Protein Ligases | 2013 |
Epigenetic upregulation of alpha-synuclein in the rats exposed to methamphetamine.
Topics: alpha-Synuclein; Amphetamine-Related Disorders; Animals; Behavior, Animal; Cytokines; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Humans; Male; Methamphetamine; Methyl-CpG-Binding Protein 2; Parkinson Disease; Promoter Regions, Genetic; Rats; Rats, Wistar; RNA, Messenger; Substantia Nigra; Up-Regulation | 2014 |
Step Sequence Is a Critical Gait Parameter of Unilateral 6-OHDA Parkinson's Rat Models.
Topics: Animals; Disease Models, Animal; Gait; Locomotion; Male; Mesencephalon; Methamphetamine; Neurons; Oxidopamine; Parkinson Disease; Rats, Long-Evans; Rotation; Tyrosine 3-Monooxygenase | 2017 |
Optimized temporal pattern of brain stimulation designed by computational evolution.
Topics: Animals; Basal Ganglia; Behavior, Animal; Brain; Computer Simulation; Deep Brain Stimulation; Disease Models, Animal; Electrophysiology; Female; Humans; Male; Methamphetamine; Oscillometry; Parkinson Disease; Rats; Rats, Long-Evans; Software; Time Factors; Treatment Outcome | 2017 |
Nigrostriatal alterations in bone morphogenetic protein receptor II dominant negative mice.
Topics: Analysis of Variance; Animals; Behavior, Animal; Bone Morphogenetic Protein Receptors, Type II; Cell Death; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; In Situ Nick-End Labeling; Male; Methamphetamine; Mice; Mice, Knockout; Motor Activity; Neurons; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase | 2008 |
Differential expression of Fos and Zif268 in the nigrostriatal system after methamphetamine administration in a rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Early Growth Response Protein 1; Gene Expression Regulation; Genes, fos; Male; Methamphetamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra | 2008 |
Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
Topics: Adult; Analysis of Variance; Brain Mapping; Central Nervous System Stimulants; Corpus Striatum; Female; Humans; Magnetic Resonance Imaging; Male; Methamphetamine; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Substance Withdrawal Syndrome; Tetrabenazine; Time Factors; Vesicular Monoamine Transport Proteins | 2008 |
Detection of levorotatory methamphetamine and levorotatory amphetamine in urine after ingestion of an overdose of selegiline.
Topics: Adult; Amphetamine; Biomarkers; Drug Overdose; Gas Chromatography-Mass Spectrometry; Humans; Male; Methamphetamine; Parkinson Disease; Selegiline; Suicide, Attempted | 2008 |
Methamphetamine fails to alter the noradrenergic integrity of the heart.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Denervation; Dopamine Agonists; Heart; Humans; Hypotension, Orthostatic; Levodopa; Male; Methamphetamine; Mice; Mice, Inbred C57BL; Neurotoxins; Norepinephrine; Parkinson Disease | 2008 |
Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease.
Topics: Animals; Carbon Radioisotopes; Cells, Cultured; Cocaine; Disease Models, Animal; Dopamine; Dopamine Agents; Embryonic Stem Cells; Levodopa; Macaca fascicularis; Methamphetamine; Movement Disorders; Neurons; Parkinson Disease; Positron-Emission Tomography; Putamen; Raclopride; Tyrosine 3-Monooxygenase | 2009 |
Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
Topics: Administration, Oral; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Hydrogen; Immunohistochemistry; Injections, Intraperitoneal; Male; Methamphetamine; Microinjections; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2009 |
Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration.
Topics: Aldehydes; Animals; Blotting, Western; Chromatography, High Pressure Liquid; Corpus Striatum; Drug Synergism; Lipopolysaccharides; Male; Malondialdehyde; Methamphetamine; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease | 2010 |
Vitamin B12-impaired metabolism produces apoptosis and Parkinson phenotype in rats expressing the transcobalamin-oleosin chimera in substantia nigra.
Topics: Animals; Apoptosis; Behavior, Animal; Cell Line, Tumor; Cell Survival; Humans; Intracellular Space; Methamphetamine; Mice; Necrosis; Parkinson Disease; Plant Proteins; Plasmids; Protein Transport; Rats; Recombinant Fusion Proteins; Substantia Nigra; Transcobalamins; Transfection; Transgenes; Vitamin B 12 | 2009 |
Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease.
Topics: Actins; Animals; Brain Injuries; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Proliferation; Cell Survival; Culture Media; Culture Media, Serum-Free; Epidermal Growth Factor; Epigenesis, Genetic; Fibroblast Growth Factor 2; Gene Expression; Humans; Intermediate Filament Proteins; Locomotion; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Methamphetamine; Nerve Tissue Proteins; Nestin; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, trkB; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 2010 |
The different performance among motor tasks during the increasing current intensity of deep brain stimulation of the subthalamic nucleus in rats with different degrees of the unilateral striatal lesion.
Topics: Animals; Central Nervous System Stimulants; Corpus Striatum; Deep Brain Stimulation; Disease Models, Animal; Male; Methamphetamine; Microinjections; Motor Skills; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2010 |
Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders.
Topics: Aged; Amphetamine-Related Disorders; California; Central Nervous System Stimulants; Cohort Studies; Community Health Planning; Comorbidity; Female; Humans; Incidence; Male; Methamphetamine; Middle Aged; Parkinson Disease; Patient Discharge; Proportional Hazards Models; Risk Factors | 2010 |
Methamphetamine-induced dopamine-independent alterations in striatal gene expression in the 6-hydroxydopamine hemiparkinsonian rats.
Topics: Animals; Chromatography, High Pressure Liquid; Corpus Striatum; DNA-Binding Proteins; Dopamine; Dopamine Uptake Inhibitors; Early Growth Response Protein 1; Gene Expression Regulation; Male; Methamphetamine; Nerve Tissue Proteins; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2010 |
A Caenorhabditis elegans p38 MAP kinase pathway mutant protects from dopamine, methamphetamine, and MDMA toxicity.
Topics: Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Dopamine; Dopamine Agents; Immunity, Innate; Methamphetamine; Mutation; N-Methyl-3,4-methylenedioxyamphetamine; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Protein Serine-Threonine Kinases; Serotonin Agents; Signal Transduction | 2011 |
Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease.
Topics: Aging; Animals; Brain; Central Nervous System Stimulants; Chlorocebus aethiops; Dopamine; Glial Cell Line-Derived Neurotrophic Factor; Methamphetamine; Neurons; Parkinson Disease; Tissue Distribution; Tyrosine 3-Monooxygenase | 2011 |
Meth use linked to risk of Parkinson disease.
Topics: Amphetamine-Related Disorders; California; Central Nervous System Stimulants; Cohort Studies; Humans; Methamphetamine; Parkinson Disease; Retrospective Studies; Risk | 2011 |
Pharmacological modulation of amphetamine-induced dyskinesia in transplanted hemi-parkinsonian rats.
Topics: Animals; Anti-Dyskinesia Agents; Cell Transplantation; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Dyskinesias; Excitatory Amino Acid Antagonists; Female; Mesencephalon; Methamphetamine; Neostriatum; Nerve Tissue Proteins; Neurons; Parkinson Disease; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Neurotransmitter; Serotonin Receptor Agonists | 2012 |
Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Association Learning; Benzothiazoles; Conditioning, Operant; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Forelimb; Male; Methamphetamine; Motor Activity; Nucleus Accumbens; Oxidopamine; Parkinson Disease; Pramipexole; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reward; Tyrosine 3-Monooxygenase | 2012 |
Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis.
Topics: alpha-Synuclein; Binding Sites; Circular Dichroism; Dopaminergic Neurons; Humans; In Vitro Techniques; Lewy Bodies; Lewy Body Disease; Methamphetamine; Models, Molecular; Nanopores; Parkinson Disease; Protein Binding; Protein Conformation; Protein Folding | 2012 |
Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease.
Topics: Aged; Amphetamine; Antiparkinson Agents; Drug Substitution; Female; Humans; Indans; Male; Methamphetamine; Middle Aged; Motor Activity; Neuroprotective Agents; Parkinson Disease; Selegiline; Severity of Illness Index; Time Factors | 2013 |
Golgi fragmentation is Rab and SNARE dependent in cellular models of Parkinson's disease.
Topics: Animals; Golgi Apparatus; Homeostasis; Methamphetamine; Models, Biological; Oxidopamine; Parkinson Disease; PC12 Cells; rab GTP-Binding Proteins; Rats; SNARE Proteins; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
Endogenous dopamine release after pharmacological challenges in Parkinson's disease.
Topics: Aged; Binding Sites; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Female; Fluorodeoxyglucose F18; Humans; Male; Methamphetamine; Middle Aged; Parkinson Disease; Putamen; Raclopride; Radiopharmaceuticals; Severity of Illness Index; Synapses; Tomography, Emission-Computed | 2003 |
Retraction. Paper on toxic party drug is pulled over vial mix-up.
Topics: Animals; Dopamine; Drug Labeling; Humans; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Neurons; Parkinson Disease; Primates; Retraction of Publication as Topic; Risk Factors | 2003 |
Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Drug Interactions; Estrogens; Female; Methamphetamine; Mice; Neostriatum; Neural Pathways; Neuroprotective Agents; Neurotoxins; Ovariectomy; Parkinson Disease; Presynaptic Terminals; Reaction Time; Sex Factors; Substantia Nigra | 2003 |
Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Electrochemistry; Immunohistochemistry; Male; Methamphetamine; Nerve Growth Factors; Oxidopamine; Parkinson Disease; Potassium; Rats; Rats, Inbred F344; Tyrosine 3-Monooxygenase | 2004 |
Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway.
Topics: Animals; Apoptosis; Carbazoles; Cell Line; Cells, Cultured; Cystine; Cytosol; Dopamine; Enzyme Activation; Ferrous Compounds; Glutathione; Humans; Hydrogen Peroxide; Indoles; JNK Mitogen-Activated Protein Kinases; Lipid Peroxidation; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mesencephalon; Methamphetamine; Nerve Degeneration; Neurites; Neurons; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Superoxides | 2005 |
Dopamine covalently modifies and functionally inactivates parkin.
Topics: Adult; Animals; Blotting, Western; Brain Chemistry; Carbon Radioisotopes; Cell Line; Cells, Cultured; CHO Cells; Cricetinae; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Locus Coeruleus; Methamphetamine; Mutation; Neurons; Parkinson Disease; Precipitin Tests; Solubility; Substantia Nigra; Ubiquitin-Protein Ligases | 2005 |
High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users.
Topics: Amphetamine; Amphetamines; Antiparkinson Agents; Chromatography, High Pressure Liquid; Hair; Humans; Methamphetamine; Parkinson Disease; Selegiline; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection | 2006 |
Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Androgens; Animals; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Estradiol; Estrogen Antagonists; Female; Methamphetamine; Mice; Neostriatum; Nerve Degeneration; Neuroprotective Agents; Neurotoxins; Ovariectomy; Parkinson Disease; Substantia Nigra; Tamoxifen | 2006 |
Nitric oxide-containing neurons in long-term grafts in a rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Choline; Disease Models, Animal; Female; Indazoles; Methamphetamine; NADPH Dehydrogenase; Neostriatum; Neurons; Nitric Oxide; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Pregnancy; Rats; Rats, Sprague-Dawley; Rotation; Somatostatin; Time Factors; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2007 |
Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease.
Topics: Amphetamine; Humans; Hydrogen-Ion Concentration; Methamphetamine; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Combinations; Female; Humans; Levodopa; Male; Methamphetamine; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Tyramine | 1982 |
The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
Topics: Amphetamine; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrogen-Ion Concentration; Levodopa; Methamphetamine; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1982 |
Strands of embryonic mesencephalic tissue show greater dopamine neuron survival and better behavioral improvement than cell suspensions after transplantation in parkinsonian rats.
Topics: Animals; Behavior, Animal; Cell Size; Cell Survival; Cell Transplantation; Dopamine; Fetal Tissue Transplantation; Graft Survival; Male; Mesencephalon; Methamphetamine; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stereotyped Behavior | 1998 |
Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient.
Topics: Aged; Binding Sites; Brain Tissue Transplantation; Caudate Nucleus; Dopamine; Fetal Tissue Transplantation; Graft Survival; Humans; Male; Methamphetamine; Middle Aged; Neurons; Parkinson Disease; Putamen; Raclopride; Receptors, Dopamine D2; Substantia Nigra; Synapses; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 1999 |
Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alcohol Dehydrogenase; Antioxidants; Apoptosis; Catalase; Chromatography, High Pressure Liquid; Dopamine; Hydrogen-Ion Concentration; Methamphetamine; Monophenol Monooxygenase; Nerve Tissue Proteins; Neurons; Nitrates; Nitric Oxide; Nitrites; Oxidants; Oxidation-Reduction; Parkinson Disease; Protein Binding; Sulfhydryl Compounds; Superoxide Dismutase | 1999 |
Dopa-producing astrocytes generated by adenoviral transduction of human tyrosine hydroxylase gene: in vitro study and transplantation to hemiparkinsonian model rats.
Topics: Adenoviridae; Animals; Animals, Newborn; Apomorphine; Astrocytes; beta-Galactosidase; Cells, Cultured; Corpus Striatum; Dihydroxyphenylalanine; Female; Genetic Vectors; Graft Rejection; Humans; Immunosuppressive Agents; Methamphetamine; Mice; Mice, Inbred ICR; Parkinson Disease; Postural Balance; Rats; Rats, Wistar; Sensation Disorders; Tacrolimus; Transfection; Tyrosine 3-Monooxygenase | 1999 |
Protection of methamphetamine nigrostriatal toxicity by dietary selenium.
Topics: Animals; Body Weight; Corpus Striatum; Dopamine; Dopamine Agents; Glutathione; Glutathione Peroxidase; Male; Methamphetamine; Mice; Mice, Inbred C57BL; Parkinson Disease; Selenium; Substantia Nigra; Superoxide Dismutase | 1999 |
Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure.
Topics: Animals; Carrier Proteins; Chlorocebus aethiops; Corpus Striatum; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Glial Fibrillary Acidic Protein; Male; Membrane Glycoproteins; Membrane Transport Proteins; Methamphetamine; Nerve Fibers; Nerve Tissue Proteins; Neuropeptides; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2000 |
Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites.
Topics: Adrenergic Agents; Apoptosis; Caspase 3; Caspases; Cell Survival; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Melanoma; Methamphetamine; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Proadifen; Selegiline; Tumor Cells, Cultured | 2001 |
Multiplex three-dimensional brain gene expression mapping in a mouse model of Parkinson's disease.
Topics: Animals; Brain Chemistry; Brain Mapping; Central Nervous System Stimulants; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Methamphetamine; Mice; Mice, Inbred C57BL; Multigene Family; Parkinson Disease; Parkinson Disease, Secondary | 2002 |
Xenografts of MHC-deficient mouse embryonic mesencephalon improve behavioral recovery in hemiparkinsonian rats.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Histocompatibility Antigens Class II; Immunohistochemistry; Major Histocompatibility Complex; Male; Mesencephalon; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Recovery of Function; Sympatholytics; Time Factors; Transplantation, Heterologous; Transplantation, Heterotopic; Tyrosine 3-Monooxygenase | 2002 |
Motor impairments after methamphetamine-induced neurotoxicity in the rat.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Dopamine; Fenfluramine; Levodopa; Male; Methamphetamine; Motor Activity; Nervous System Diseases; Parkinson Disease; Rats; Serotonin | 1992 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Fluphenazine; Levodopa; Male; Methamphetamine; Microinjections; Parkinson Disease; Rats; Sulpiride | 1990 |
Reserpine rigidity in the rat--a model for the analysis of antiparkinson drugs.
Topics: 1-Propanol; Animals; Biperiden; Cerebral Decortication; Electromyography; Methamphetamine; Models, Neurological; Motor Neurons; Movement Disorders; Parasympatholytics; Parkinson Disease; Piperidines; Rats; Reserpine | 1968 |